TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06560112
Drug: AK112
Normalized name: IMMUNOGLOBULIN G1 (240-ALANINE,241-ALANINE), ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL AK112 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED CELL
DrugBank: Ivonescimab (DB18931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivgtt
Study: NCT05161780
Drug: Lactated Ringer's Irrigation
Normalized name: Lactated Ringer'S Irrigation
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringers at 40C will be used for the entirety of the surgery including the approach and exposure of the tumor as well as tumor resection, After surgery, two blinded skull base surgeon reviewers will rate the clarity of the endoscopic field of view at the recorded intervals. The surgical field will be graded using a widely accepted numeric integer (Boezaart) scale.
Study: NCT00002269
Drug: Ampligen
DrugBank: Rintatolimod (DB16425)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002269
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05979051
Drug: SHR-1703
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1703 will be administered by Subcutaneous injection in Phase 2 and Phase 3.
Study: NCT05976217
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg daily by mouth for 3 weeks This drug inhibits a protein (Bcl-2) that protects cells from undergoing programmed cell death.
Study: NCT05489523
Drug: Tafamidis 61 MG
Normalized name: tafamidis 61 MG
DrugBank: Tafamidis (DB11644)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tafamidis 61 mg by mouth daily for 12 months
Study: NCT06116240
Drug: Pemetrexed disodium for injection
Normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed disodium is a multi-target antifolate antineoplastic drug.
Study: NCT06116240
Drug: Cisplatin injection
Normalized name: cisplatin Injection
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin is a chemotherapy drug.
Study: NCT06471829
Drug: Lu AG13909
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection/infusion
Study: NCT04872790
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT04872790
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04872790
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05831345
Drug: Methadone Hydrochloride
Normalized name: Methadone Hydrochloride
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classic induction of anesthesia (opioid, hypnotic and curare) but the team is blinded to the opioid used (sufentanil or methadone), which is prepared in identical syringes by the pharmacy
Study: NCT06495944
Drug: Dazucorilant
Normalized name: Dazucorilant
DrugBank: Dazucorilant (DB18025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg soft gelatin capsules formulation for oral administration
Study: NCT06495944
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg capsules for oral administration
Study: NCT04783675
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (375 mg/m2) will be given as a single intravenous infusion after remission
Study: NCT05251948
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab is administered by IV infusion on Day 1 of each 21 day cycle. Treatment until progressive disease.
Study: NCT05251948
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin is administered by IV infusion on Day 1 of each 21 day cycle. Treatment for up to six cycles.
Study: NCT05251948
Drug: Tiragolumab
Normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiragolumab is administered by IV infusion on Day 1 of each 21 day cycle.
Study: NCT05299931
Drug: Ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: dose escalation from every 8 weeks to every 4 weeks only in arm 2
Study: NCT06523595
Drug: VX-993
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension for Oral Administration.
Study: NCT06523595
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets for Oral Administration.
Study: NCT05315999
Drug: Palonosetron Hydrochloride
Normalized name: Palonosetron Hydrochloride
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palonosetron (500µg): single dose per os 1-2 hours before the start of opioid-therapy (WHO II \& III)
Study: NCT06208215
Drug: RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants ≥1 year old who receive SOC therapy and 5 mg/kg of RZ358 or placebo
Study: NCT06208215
Drug: RZ358 (10 mg/kg) or Placebo + SOC
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants ≥1 year old who receive SOC therapy and 10 mg/kg of RZ358 or placebo
Study: NCT06208215
Drug: RZ358 (5-10 mg/kg) + SOC
Normalized name: Immunoglobulin G2, anti-(human insulin receptor) (human monoclonal RZ358 γ2-chain), disulfide with human monoclonal RZ358 κ-chain, dimer
DrugBank: Ersodetug (DB18182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant participants from ≥3 months to \<1 year old who receive SOC therapy + RZ358 starting at 5 mg/kg and increasing to 10 mg/kg of RZ358, as needed, per the protocol schedule
Study: NCT04932434
Drug: Psilocybin therapy
Normalized name: Monistat Simple Therapy
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Psilocybin administration session 1: 10mg delivered orally with psychological support and monitoring~* Psilocybin administration session 2: 25mg delivered orally with psychological support and monitoring
Study: NCT05874544
Drug: Vonoprazan
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Proton pump inhibitor
Study: NCT05874544
Drug: Bismuth Potassium Citrate
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study: NCT05874544
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotics for H. pylori eradication
Study: NCT05874544
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotics for H. pylori eradication
Study: NCT05874544
Drug: Rifabutin
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotics for H. pylori eradication
Study: NCT05964465
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monoclonal antibody blocking interleukin 4 and interleukin 13
Study: NCT05161598
Drug: Teclistamab
Normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teclistamab will be administered subcutaneously (SC).
Study: NCT05493761
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 60 mg (1ml) administered subcutaneously once every 6 months for 12 months (totally 2 injections). Patients will also be supplemented with calcium carbonate (1000 mg/d) and cholecalciferol (800 IU/day), according to the recent guidelines.
Study: NCT05493761
Drug: Alendronate Sodium
Normalized name: Alendronate Sodium
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 70 mg (1 tablet) administered per os once weekly for 12 months. Patients will also be supplemented with calcium carbonate (1000 mg/d) and cholecalciferol (800 IU/day), according to the recent guidelines.
Study: NCT05381597
Drug: 5-fluorouracil cream
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Apply the cream to the size of their lesion extending to the 0.5 cm area of skin surrounding the lesion twice daily for 28 days.
Study: NCT06250400
Drug: Loratadine 10 Mg
Normalized name: loratadine 10 MG
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: orally, 10mg once a day for 4 weeks
Study: NCT04702581
Drug: PCV chemotherapy
Normalized name: PCV
DrugBank: Penciclovir (DB00299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. cycle of PCV chemotherapy is given as:~   * Day 1: CCNU 110 mg/m2 orally;~  * Days 8 and 29: Vincristine 1.4 mg/m2 IV;~  * Days 8 to 21: Procarbazine 60 mg/m2 orally~6 cycles are given.
Study: NCT04702581
Drug: Radiotherapy and PCV chemotherapy
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Radiotherapy will deliver 50.4 Gy in 28 fractions of 1.8 Gy using IMRT technique.~Followed by 6 cycles of PCV chemotherapy~1 cycle of PCV is given as:~* Day 1: CCNU 110 mg/m2 orally;~* Days 8 and 29: Vincristine 1.4 mg/m2 IV;~* Days 8 to 21: Procarbazine 60 mg/m2 orally
Study: NCT04800666
Drug: Mecobalamin Tablets
Normalized name: mecobalamin Oral Tablet
DrugBank: Mecobalamin (DB03614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral Mecobalamin Tablets tid-8
Study: NCT04149275
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment with oral Cabozantinib once daily
Study: NCT04149275
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV administration of Ipilimumab on 21 day cycles
Study: NCT04149275
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV administration of Nivolumab on 21 day cycles, followed by Nivolumab maintenance on 28 day cycles
Study: NCT05820893
Drug: Resistant Potato Starch
Normalized name: Potato Starch
DrugBank: Potato (DB10562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSPrebiotic (MSPrebiotic Inc, Carberry, Manitoba, Canada). MSPrebiotic is an unmodified resistant starch derived from potatoes (Solanar tuberosum). It consists of 20% amylose and 80% amylopectin forming granules the stomach and small intestine are unable to digest allowing for absorption in the colon. MSPrebiotic is consumed by mixing 10g into cold or room temperature foods or beverages; it is not to be heated. Participants will be instructed to take MSPrebiotic 2 or more hours before or after consuming any medications.
Study: NCT04426968
Drug: Pegylated Interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180 ug/week subcutaneously (s.c.) for 28 week
Study: NCT03897075
Drug: Tildrakizumab
Normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up
Study: NCT06427005
Drug: Fruquintinib
Normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib 5 mg daily for 14 days followed by a 7-day break
Study: NCT06427005
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: S-1 80-120 mg daily for 14 days, followed by a 7-day break
Study: NCT06427005
Drug: raltitrexed
Normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: raltitrexed 3 mg/m² on day 1, with a maximum dose of 5 mg
Study: NCT06416111
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine is a potent local anesthetic with unique characteristics from the amide group of local anesthetics.
Study: NCT06416111
Drug: Prilocaine
Normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prilocaine is an amide local anesthetic secondary amine with an intermediate length of duration and quick onset of action.
Study: NCT06799169
Drug: Nortriptyline
Normalized name: Nortriptyline
DrugBank: Nortriptyline (DB00540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nortriptyline (7.5 mg) plus Topiramate (10 mg) taken by mouth daily with appropriate dosage increase as necessary
Study: NCT06799169
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nortriptyline (7.5 mg) plus Topiramate (10 mg) taken by mouth daily with appropriate dosage increase as necessary
Study: NCT06799169
Drug: Paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil (30 mg) plus Paroxetine (4 mg) taken by mouth daily with appropriate dosage increase as necessary
Study: NCT06799169
Drug: Verapamil
Normalized name: Verapamil
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil (30 mg) plus Paroxetine (4 mg) taken by mouth daily with appropriate dosage increase as necessary
Study: NCT05564611
Drug: Omalizumab 150mg
Normalized name: OMALIZUMAB 150MG/VIL INJ
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single dose of 150 mg lyophilized vial will be administered in the upper arm as the site of injection
Study: NCT06800274
Drug: azelastine hydrochloride 0.05%
Normalized name: Azelastine Hydrochloride 0.05% Ophthalmic Solution
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 54 patients were randomly assigned to azelastine hydrochloride 0.05% instilled as 1 drop per eye 2 times a day in the conjunctival sac for for four weeks. Specific diagnostic tests and procedures for dry eye disease were performed at week 0 (baseline), week 2 and week 4.
Study: NCT06189209
Drug: Tenalisib
Normalized name: Tenalisib
DrugBank: Tenalisib (DB15295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenalisib will be administered 800mg/ 400mg BID, orally
Study: NCT05512390
Drug: ABBV-319
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV); Infusion
Study: NCT06206291
Drug: Cannabidiol (CBD) 200mg
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: First 4 weeks: CBD (200mg)/Placebo twice daily adjunct with opioid agonist treatment.
Study: NCT06206291
Drug: Cannabidiol (CBD) 400mg
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Second 4 weeks: All cohorts receive CBD (400mg) twice daily adjunct with opioid agonist treatment.
Study: NCT05858515
Drug: Baricitinib 4 MG
Normalized name: baricitinib 4 MG
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nonproprietary name: Baricitinib
Study: NCT05578001
Drug: Pilocarpine Ophthalmic
Normalized name: pilocarpine ophthalmic
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 drop of Pilocarpine 1%
Study: NCT05904119
Drug: Lomustine
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Lomustine
Study: NCT06021197
Drug: NMDAE
Normalized name: NMDA
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of an NMDA enhancer for the treatment of CIAS
Study: NCT05857384
Drug: Acetazolamide 250 MG
Normalized name: acetazolamide 250 MG
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A solid tablet containing 250 mg acetazolamide
Study: NCT05857384
Drug: Dronabinol 2.5 MG
Normalized name: dronabinol 2.5 MG
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A soft gelatin capsules containing 2.5mg dronabinol
Study: NCT05955508
Drug: Linvoseltamab
Normalized name: Linvoseltamab
DrugBank: Linvoseltamab (DB17447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous (IV) infusion
Study: NCT06419205
Drug: ADX-097
Normalized name: ADX 102
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open Label
Study: NCT05391061
Drug: Abrocitinib
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets
Study: NCT05374525
Drug: APRETUDE
Normalized name: Apretude
DrugBank: Cabotegravir (DB11751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Available as intramuscular injection.
Study: NCT05374525
Drug: Cabotegravir OLI
DrugBank: Cabotegravir (DB11751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Available as marketed orally administered tablets.
Study: NCT06091267
Drug: IV Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subjects will receive decitabine 20 mg/m\^2 IV daily × 5 days in 28-day cycles.
Study: NCT05888870
Drug: SCT800 and Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SCT800 50IU/kg TIW alone or treated with Daratumumab 8mg/kg 4-8 times
Study: NCT05888870
Drug: SCT800
Normalized name: 1-740-BLOOD COAGULATION FACTOR VIII (RECOMBINANT HUMAN SCT800 HEAVY CHAIN) FUSION PROTEIN WITH HUMAN BLOOD COAGULATION FACTOR VIII B DOMAIN FRAGMENT (14-AMINO ACID LINKER) FUSION PROTEIN WITH BLOOD COAGULATION FACTOR VIII (RECOMBINANT HUMAN SCT800 LIGHT
DrugBank: Omfiloctocog alfa (DB19229)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCT800 50IU/kg TIW alone
Study: NCT06119581
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV.
Study: NCT06119581
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT06119581
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered IV.
Study: NCT06119581
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered IV.
Study: NCT04507178
Drug: Nadroparin Injectable Product
Normalized name: nadroparin Injectable Product
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: high dose LMWH compared to prophylactic dose LMWH
Study: NCT06434064
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05642208
Drug: Dupilumab step-down
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: step down dupilumab injections
Study: NCT06279221
Drug: LITFULO
Normalized name: Litfulo
DrugBank: Ritlecitinib (DB14924)
Approvals — FDA: no, EMA: no, PMDA: no
Description: as provided in real world practice
Study: NCT05650775
Drug: Concerta
Normalized name: Concerta
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-week trial of oral methylphenidate extended release
Study: NCT05650775
Drug: Adderall-XR
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-week trial of oral mixed amphetamine salts, extended release, administered only to children who do not show at least 30% improvement during the Concerta/Methylphenidate trial.
Study: NCT05177237
Drug: Endostar
Normalized name: Endostar
DrugBank: Endostar (DB11727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endostar: 210 mg (14 PCS) continuous infusion for 168h, Q3W, 4 cycles. Methylprednisolone: 80mg intravenously, once daily, for 3-5 days, gradually reduced to 10mg/ day oral maintenance dose.
Study: NCT06051045
Drug: Bulevirtide
Normalized name: Bulevirtide
DrugBank: Bulevirtide (DB15248)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Hepcludex, 2 mg daily subcutaneous injection
Study: NCT06506084
Drug: Ropeginterferon alfa-2b
Normalized name: Ropeginterferon alfa-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Data will be collected at each visit during the observational study (total duration: 24 months). In accordance with routine clinical practice in this patient population, visits are expected to take place every 6 months.~Patients who discontinue ropeginterferon alfa-2b treatment at any time will no longer be followed up.
Study: NCT06455059
Drug: Vosoritide
Normalized name: VOSORITIDE
DrugBank: Vosoritide (DB11928)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous injection of recommended dose of vosoritide based on weight-band dosing once daily.
Study: NCT06564389
Drug: PF-07832837
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: escalated doses of PF-07832837
Study: NCT06171217
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea, approximately 20-30 mg/kg/day, with modifications for toxicity or for mild marrow suppression
Study: NCT06171217
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea 15-35 mg/kg/day based on PK-guided dosing, with modifications for toxicity for mild marrow suppression
Study: NCT05183204
Drug: Paxalisib
Normalized name: Paxalisib
DrugBank: Paxalisib (DB15186)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive paxalisib starting at a dose of 45 mg/day. If well tolerated after 28 days, the dose of paxalisib will be increased to 60 mg/day.
Study: NCT05183204
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive metformin on Cycle 1, Day 1 at a starting dose of 850 mg QD, and if tolerated, will be increased to 850 mg BID on Cycle 2, Day 1 (1700 mg/day). If that dose is tolerated, metformin will be increased to 850 mg TID (2550 mg/day) beginning on Cycle 3, Day 1.
Study: NCT04284787
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV or SC
Study: NCT05117632
Drug: ALTO-100 PO tablet
Normalized name: Altoprev
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one tablet twice daily
Study: NCT06111547
Drug: TAK-279
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-279 oral tablet.